IST:ONCSM's ROE % is ranked better than 82.1% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs IST:ONCSM: 12.87
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROE % Related Terms
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROE % Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROE % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a ROE % of 5.57% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. This is 60% above median its historical median of 3.48. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #143 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 17.9%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROE % of 5.57% is 60% above median its 10-year median of 3.48. The Medical Devices & Instruments industry median ROE % is 2.42. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 5.57% is 130.2% above this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #143 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #143 out of 799 companies for ROE %. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the top 18% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 5.57% is 130.2% above this benchmark. While the company's 10-year median is 3.48 vs. the industry median of 2.42, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROE % of 5.57% is 130.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROE % is 5.57%, which is 60% above median its own 10-year median of 3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺252.15, compared to a current price of ₺252.00 — trading 0.1% below its estimated fair value. The current ROE % is 5.57%, which is 60% above median its 10-year median of 3.48 and 130.2% above the Medical Devices & Instruments industry median of 2.42. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current ROE % is 5.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued.
The current stock price of ₺252.00 is trading 0.1% below its estimated GF Value™ of ₺252.15.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
ROE %: 5.57% (60% above median its 10-year median of 3.48)
GF Value™: ₺252.15 vs. price of ₺252.00 (0.1% below fair value)
Industry Position: 130.2% above the Medical Devices & Instruments median (#143 of 799)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
